{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:22:18Z","timestamp":1778696538687,"version":"3.51.4"},"reference-count":135,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.metabol.2015.07.011","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T03:49:27Z","timestamp":1437450567000},"page":"1199-1214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Novel therapies for osteoporosis"],"prefix":"10.1016","volume":"64","author":[{"given":"Polyzois","family":"Makras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sideris","family":"Delaroudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios D.","family":"Anastasilakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2015.07.011_bb0005","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2147\/TCRM.S24239","article-title":"Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab","volume":"8","author":"Anastasilakis","year":"2012","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.metabol.2015.07.011_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2015.07.011_bb0015","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1517\/13543780903048929","article-title":"RANKL inhibition for the management of patients with benign metabolic bone disorders","volume":"18","author":"Anastasilakis","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.metabol.2015.07.011_bb0020","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2015.07.011_bb0030","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"420","article-title":"Denosumab","author":"McClung","year":"2013"},{"key":"10.1016\/j.metabol.2015.07.011_bb0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1210\/jc.2010-1805","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial","volume":"96","author":"Miller","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0040","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/cen.12188","article-title":"Parathyroid hormone changes following denosumab treatment in postmenopausal osteoporosis","volume":"79","author":"Makras","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2015.07.011_bb0045","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.metabol.2015.07.011_bb0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2015.07.011_bb0055","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1517\/17425255.2015.1000860","article-title":"Denosumab for the treatment of osteoporosis","volume":"11","author":"Zaheer","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0060","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0065","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0070","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1210\/jc.2014-1154","article-title":"An open-label, prospective pilot clinical study of denosumab for severe hyperparathyroidism in patients with low bone mass undergoing dialysis","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0075","doi-asserted-by":"crossref","first-page":"30","DOI":"10.14712\/18059694.2014.6","article-title":"Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature","volume":"57","author":"Dusilova Sulkova","year":"2014","journal-title":"Acta Med (Hradec Kralove)"},{"key":"10.1016\/j.metabol.2015.07.011_bb0080","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0085","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/AOG.0b013e318291718c","article-title":"Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trial","volume":"121","author":"Recknor","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bone.2013.10.006","article-title":"Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study","volume":"58","author":"Roux","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2015.06.018","article-title":"Denosumab in treatment-na\u00efve and pre-treated with zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers","author":"Anastasilakis","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2015.07.011_bb0100","series-title":"ASBMR 2013 Annual Meeting. Baltimore, Maryland, USA","article-title":"Eight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the FREEDOM extension","author":"Papapoulos","year":"2013"},{"key":"10.1016\/j.metabol.2015.07.011_bb0105","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0110","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00198-012-2052-4","article-title":"Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial","volume":"24","author":"McClung","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0115","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0125","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2015.07.011_bb0130","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.metabol.2015.07.011_bb0135","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","article-title":"Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial","volume":"28","author":"Brown","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0140","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.beem.2014.09.002","article-title":"Current and future treatments of osteoporosis in men","volume":"28","author":"Kaufman","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0145","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1210\/jc.2012-1569","article-title":"A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density","volume":"97","author":"Orwoll","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0150","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2015.07.011_bb0155","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0160","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2013-3795","article-title":"Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis","volume":"99","author":"Mandema","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0165","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0170","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","article-title":"Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women","volume":"23","author":"Freemantle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0175","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0180","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2015.07.011_bb0185","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.semarthrit.2011.03.005","article-title":"Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis","volume":"41","author":"von Keyserlingk","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.metabol.2015.07.011_bb0190","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00198-011-1755-2","article-title":"Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?","volume":"23","author":"Watts","year":"2012","journal-title":"Osteoporos Int"},{"issue":"Suppl. 1","key":"10.1016\/j.metabol.2015.07.011_bb0195","article-title":"Findings from denosumab (Prolia\u00ae) post-marketing safety surveillance for atypical femoral fracture, osteonecrosis of the jaw, severe symptomatic hypocalcemia, and anaphylaxis","volume":"29","author":"Geller","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0200","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2015.07.011_bb0205","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/DDDT.S47807","article-title":"Profile of bazedoxifene\/conjugated estrogens for the treatment of estrogen deficiency symptoms and osteoporosis in women at risk of fracture","volume":"7","author":"Rossini","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.metabol.2015.07.011_bb0210","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/gme.0b013e3181906fa3","article-title":"Designing the ideal selective estrogen receptor modulator\u2014an achievable goal?","volume":"16","author":"Taylor","year":"2009","journal-title":"Menopause"},{"key":"10.1016\/j.metabol.2015.07.011_bb0215","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","article-title":"Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial","volume":"291","author":"Anderson","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2015.07.011_bb0220","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0225","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2015.07.011_bb0230","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2015.07.011_bb0235","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1517\/14656566.2013.844790","article-title":"Bazedoxifene+conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause","volume":"14","author":"Tella","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.metabol.2015.07.011_bb0240","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0245","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0250","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.metabol.2015.07.011_bb0255","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11914-011-0085-9","article-title":"Inhibition of cathepsin K for treatment of osteoporosis","volume":"10","author":"Boonen","year":"2012","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.metabol.2015.07.011_bb0260","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1359\/JBMR.040603","article-title":"Intracellular machinery for matrix degradation in bone-resorbing osteoclasts","volume":"19","author":"V\u00e4\u00e4r\u00e4niemi","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0265","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1126\/science.273.5279.1236","article-title":"Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency","volume":"273","author":"Gelb","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.metabol.2015.07.011_bb0270","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1359\/jbmr.1999.14.10.1654","article-title":"Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization","volume":"14","author":"Gowen","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0275","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.bone.2008.08.130","article-title":"Bone density, strength, and formation in adult cathepsin K (-\/-) mice","volume":"44","author":"Pennypacker","year":"2009","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0280","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1359\/jbmr.2001.16.8.1444","article-title":"Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K","volume":"16","author":"Kiviranta","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0285","first-page":"666","article-title":"Osteoclast-specific deletion stimulates S1P-dependent bone formation","volume":"123","author":"Lotinun","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2015.07.011_bb0290","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/sj.clpt.6100450","article-title":"Cathepsin K inhibitors: a novel target for osteoporosis therapy","volume":"83","author":"Stoch","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2015.07.011_bb0295","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1517\/13543780902832661","article-title":"Cathepsin K inhibitors for osteoporosis and potential off-target effects","volume":"18","author":"Br\u00f6mme","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.metabol.2015.07.011_bb0300","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1021\/jm0504961","article-title":"Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity","volume":"48","author":"Falgueyret","year":"2005","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2015.07.011_bb0305","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2174\/13894501113149990202","article-title":"Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis","volume":"14","author":"Helali","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.metabol.2015.07.011_bb0310","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s00223-009-9279-x","article-title":"Treatment with a potent cathepsin K inhibitor preserves cortical and trabecular bone mass in ovariectomized monkeys","volume":"85","author":"Stroup","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0315","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jbmr.1477","article-title":"Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey","volume":"27","author":"Cusick","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0320","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jbmr.1475","article-title":"Odanacatib reduces bone turnover and increases bone mass in lumbar spine of skeletally mature ovariectomized rhesus monkeys","volume":"27","author":"Masarachia","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0325","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.04.023","article-title":"Effects of eight month treatment with ONO-5334, a cathepsin K inhibitor, on bone metabolism, strength and microstructure in ovariectomized cynomolgus monkeys","volume":"65","author":"Ochi","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0330","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1210\/jc.2013-2630","article-title":"Are cathepsin K inhibitors just another class of antiresorptives?","volume":"98","author":"Chambers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0335","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.beem.2014.07.003","article-title":"Novel approaches to the treatment of osteoporosis","volume":"28","author":"Appelman-Dijkstra","year":"2014","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0340","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bone.2013.06.008","article-title":"Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate","volume":"56","author":"Williams","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0345","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-011-1593-2","article-title":"Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys","volume":"23","author":"Jerome","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0350","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nrrheum.2011.77","article-title":"Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis","volume":"7","author":"Costa","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0355","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1016\/j.jaad.2010.11.033","article-title":"Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib","volume":"66","author":"R\u00fcnger","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0360","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1177\/0091270011399080","article-title":"Pharmacodynamic effects on biochemical markers of bone turnover and pharmacokinetics of the cathepsin K inhibitor, ONO-5334, in an ascending multiple-dose, phase 1 study","volume":"52","author":"Nagase","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0365","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/jbmr.2047","article-title":"Effect of ONO-5334 on bone mineral density and biochemical markers of bone turnover in postmenopausal osteoporosis: 2-year results from the OCEAN study","volume":"29","author":"Eastell","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0370","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/clpt.2009.60","article-title":"Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies","volume":"86","author":"Stoch","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2015.07.011_bb0375","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0380","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/jbmr.212","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect","volume":"26","author":"Eisman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0385","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/jbmr.1695","article-title":"Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study","volume":"27","author":"Langdahl","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0390","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1210\/jc.2013-2020","article-title":"Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial","volume":"98","author":"Bonnick","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0405","series-title":"Results from the phase III Long-term Odanacatib Fracture Trial (LOFT). ASBMR 2014. Huston, Texas","article-title":"Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis","author":"McClung","year":"2014"},{"key":"10.1016\/j.metabol.2015.07.011_bb0470","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2015.07.011_bb0475","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/jbmr.2351","article-title":"A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density","volume":"30","author":"Recker","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0530","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1210\/jc.2014-3718","article-title":"Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis","volume":"100","author":"Leder","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0535","article-title":"Bone anabolic efficacy and safety of BA058, a novel analog of hPTHrP: 12-month extension data from a phase 2 clinical trial in postmenopausal women with osteoporosis","author":"Hattersley","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0540","series-title":"ENDO 2015. San Diego, California","article-title":"Effects of abaloparatide on vertebral and non-vertebral fracture incidence in postmenopausal women with osteoporosis\u2014results of the phase 3 Active trial","author":"Miller","year":"2015"},{"key":"10.1016\/j.metabol.2015.07.011_bb0395","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1002\/jbmr.2194","article-title":"Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microstructure and estimated bone strength","volume":"29","author":"Cheung","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0400","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00198-014-2944-6","article-title":"Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial","volume":"26","author":"Bone","year":"2015","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0410","series-title":"Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III Long-term Odanacatib Fracture Trial (LOFT). ASBMR 2014. Huston, Texas","author":"Papapoulos","year":"2014"},{"key":"10.1016\/j.metabol.2015.07.011_bb0415","doi-asserted-by":"crossref","first-page":"6267","DOI":"10.1093\/emboj\/cdg599","article-title":"Osteocyte control of bone formation via sclerostin, a novel BMP antagonist","volume":"22","author":"Winkler","year":"2003","journal-title":"EMBO J"},{"key":"10.1016\/j.metabol.2015.07.011_bb0420","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2015.07.011_bb0425","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jbmr.474","article-title":"Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover","volume":"26","author":"van Lierop","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0430","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/jbmr.1794","article-title":"Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers","volume":"28","author":"van Lierop","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0435","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0440","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0445","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1002\/jbmr.14","article-title":"Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength","volume":"25","author":"Ominsky","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0450","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrendo.2014.214","article-title":"Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis","volume":"11","author":"Papapoulos","year":"2015","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0455","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/jbmr.173","article-title":"Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody","volume":"26","author":"Padhi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0460","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/jcph.239","article-title":"Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study","volume":"54","author":"Padhi","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.metabol.2015.07.011_bb0465","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women","volume":"29","author":"McColm","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0480","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s00223-013-9777-8","article-title":"Once-weekly injection of low-dose teriparatide (28.2\u03bcg) reduced the risk of vertebral fracture in patients with primary osteoporosis","volume":"94","author":"Fujita","year":"2014","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0485","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1210\/jc.2011-3479","article-title":"Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk","volume":"97","author":"Nakamura","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0490","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.bone.2012.01.009","article-title":"The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women","volume":"50","author":"Hammerle","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0495","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1007\/s00198-006-0159-1","article-title":"Daily nasal spray of hPTH(1-34) for 3months increases bone mass in osteoporotic subjects: a pilot study","volume":"17","author":"Matsumoto","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0500","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jc.2009-0358","article-title":"Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women","volume":"95","author":"Cosman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0505","series-title":"29th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) Presentation M421","article-title":"Pulmonary delivery of the parathyroid hormone analogue ostabolin-C\u2122 stimulates markers of bone formation in postmenopausal women","author":"Morley","year":"2007"},{"key":"10.1016\/j.metabol.2015.07.011_bb0510","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1517\/13543784.2015.973021","article-title":"Investigational parathyroid hormone agonists for the treatment of osteoporosis","volume":"24","author":"Polyzos","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.metabol.2015.07.011_bb0515","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bone.2012.11.045","article-title":"Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis","volume":"53","author":"Henriksen","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0520","series-title":"Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) Presentation 1130","article-title":"Ostabolin-C\u2122 increases lumbar spine and hip BMD after 1year of therapy: results of a phase II clinical trial","author":"Hodsman","year":"2007"},{"key":"10.1016\/j.metabol.2015.07.011_bb0525","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1002\/jbmr.1978","article-title":"A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study","volume":"28","author":"Horwitz","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0545","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1210\/er.2011-1060","article-title":"Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases","volume":"33","author":"Ke","year":"2012","journal-title":"Endocr Rev"},{"key":"10.1016\/j.metabol.2015.07.011_bb0550","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2265.2009.03728.x","article-title":"The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. 2010;72:752\u20137","volume":"72","author":"Anastasilakis","year":"2010","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.metabol.2015.07.011_bb0555","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/jbmr.472","article-title":"Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury","volume":"26","author":"Li","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0560","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s00198-012-2198-0","article-title":"Circulating activin-A is elevated in postmenopausal women with low bone mass: the three-month effect of zoledronic acid treatment","volume":"24","author":"Anastasilakis","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.metabol.2015.07.011_bb0565","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.bone.2010.01.370","article-title":"A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys","volume":"46","author":"Lotinun","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0570","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1359\/jbmr.081208","article-title":"Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women","volume":"24","author":"Ruckle","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0575","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.beem.2013.02.008","article-title":"Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders","volume":"27","author":"Nemeth","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0580","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.bone.2014.04.015","article-title":"AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women","volume":"64","author":"John","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.metabol.2015.07.011_bb0585","doi-asserted-by":"crossref","first-page":"E2207","DOI":"10.1210\/jc.2013-4009","article-title":"A phase 2, randomized, placebo-controlled, dose-ranging study of the calcium-sensing receptor antagonist MK-5442 in the treatment of postmenopausal women with osteoporosis","volume":"99","author":"Halse","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0590","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1002\/jbmr.554","article-title":"Ronacaleret, a calcium-sensing receptor antagonist, increases trabecular but not cortical bone in postmenopausal women","volume":"27","author":"Fitzpatrick","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0595","article-title":"The functional mechanism of simvastatin in experimental osteoporosis","author":"Dai","year":"2014","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0600","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jamainternmed.2014.6388","article-title":"Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial","volume":"175","author":"Pe\u00f1a","year":"2015","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.metabol.2015.07.011_bb0605","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1358\/dnp.2005.18.8.944546","article-title":"ClC-7 as a target for osteoporosis treatment","volume":"18","author":"Schaller","year":"2005","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.metabol.2015.07.011_bb0610","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.bbrc.2010.10.117","article-title":"ATP6v0d2 deficiency increases bone mass, but does not influence ovariectomy-induced bone loss","volume":"403","author":"Kim","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.metabol.2015.07.011_bb0615","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1359\/JBMR.050517","article-title":"A vacuolar ATPase inhibitor, FR167356, prevents bone resorption in ovariectomized rats with high potency and specificity: potential for clinical application","volume":"20","author":"Niikura","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0620","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jcb.24434","article-title":"Luteolin inhibition of V-ATPase a3-d2 interaction decreases osteoclast resorptive activity","volume":"114","author":"Crasto","year":"2013","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.metabol.2015.07.011_bb0625","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/jc.2004-2126","article-title":"Effect of L-000845704, an \u03b1v\u03b23 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"90","author":"Murphy","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2015.07.011_bb0630","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1359\/jbmr.060316","article-title":"Orally bioavailable GSK-3alpha\/beta dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo","volume":"21","author":"Kulkarni","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0635","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1038\/nm.2489","article-title":"Suppression of bone formation by osteoclastic expression of semaphorin 4D","volume":"17","author":"Negishi-Koga","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2015.07.011_bb0640","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1517\/14728222.2014.983078","article-title":"Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low-bone mass: the three-month effect of zoledronic acid, denosumab or teriparatide treatment","volume":"19","author":"Anastasilakis","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.metabol.2015.07.011_bb0645","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/jbmr.2322","article-title":"Anabolic bone formation via a site specific bone targeting delivery system by interfering with semaphorin 4D expression","volume":"30","author":"Zhang","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0650","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nature11000","article-title":"Osteoprotection by semaphorin 3A","volume":"485","author":"Hayashi","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2015.07.011_bb0655","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1359\/jbmr.090830","article-title":"Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial","volume":"25","author":"Hannon","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0660","doi-asserted-by":"crossref","first-page":"e34914","DOI":"10.1371\/journal.pone.0034914","article-title":"Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects","volume":"7","author":"Garcia-Gomez","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.metabol.2015.07.011_bb0665","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1001\/jama.2011.176","article-title":"Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial","volume":"305","author":"Jamal","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.metabol.2015.07.011_bb0670","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1359\/JBMR.0301263","article-title":"A synthetic peptide fragment of human MEPE stimulates new bone formation in vitro and in vivo","volume":"19","author":"Hayashibara","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.metabol.2015.07.011_bb0675","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/bonekey.2012.224","article-title":"The promise and dilemma of cannabinoid therapy: lessons from animal studies of bone disease","volume":"1","author":"Idris","year":"2012","journal-title":"Bonekey Rep"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049515001912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049515001912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:08:05Z","timestamp":1758427685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049515001912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":135,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0026049515001912"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2015.07.011","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies for osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2015.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}